ARS Pharmaceuticals (SPRY) Other Working Capital Changes (2020 - 2026)
ARS Pharmaceuticals (SPRY) reported Other Working Capital Changes of -$61000.0 for Q1 2026, up 70.95% on a YoY basis from -$35682.5 in Q1 2025, and down 10.91% sequentially from -$55000.0 in Q4 2025.
ARS Pharmaceuticals (SPRY) Other Working Capital Changes (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 5 years of Other Working Capital Changes data on file, last reported at -$61000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Working Capital Changes rose 70.95% year-over-year to -$61000.0; the trailing twelve-month figure through Mar 2026 stood at -$201000.0 (down 110.7% YoY), and the FY2025 full-year result was -$350000.0, down 116.75% from the prior year.
- Other Working Capital Changes eased to -$61000.0 in Q1 2026, from -$55000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $7.3 million in Q4 2024 to a low of -$4.1 million in Q2 2025.
- A 5-year average of $510588.2 and a median of -$92000.0 in 2022 frame the typical range for Other Working Capital Changes.
- Peak annual rise in Other Working Capital Changes reached 97.84% in 2023, while the deepest fall reached 371.64% in 2023.
- Tracing SPRY's Other Working Capital Changes over 5 years: stood at -$189000.0 in 2022, then surged by 94.71% to -$10000.0 in 2023, then soared by 20990.0% to $2.1 million in 2024, then slumped by 102.63% to -$55000.0 in 2025, then fell by 10.91% to -$61000.0 in 2026.
- Business Quant data shows SPRY's Other Working Capital Changes at -$61000.0 in Q1 2026, -$55000.0 in Q4 2025, and -$55000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 524,000.00 |
| Mar 31, 2026 | 524,000.00 |
| Mar 31, 2026 | 524,000.00 |
| Dec 31, 2025 | -284,000.00 |
| Dec 31, 2025 | -284,000.00 |
| Dec 31, 2025 | -284,000.00 |
| Sep 30, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -4.10 Mn |
| Jun 30, 2025 | -4.10 Mn |
| Jun 30, 2025 | -4.10 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Dec 31, 2024 | 7.25 Mn |
| Dec 31, 2024 | 7.25 Mn |
| Dec 31, 2024 | 7.25 Mn |
| Sep 30, 2024 | 504,000.00 |
| Sep 30, 2024 | 504,000.00 |